Patient-reported improvements in vision after cataract surgery are high and are unrelated to the level of ocular comorbidity or whether the surgery is in the first or second eye, report researchers.
Author: The Medical News
Prader-Willi children may receive relief from sleep disorders after adenotonsillectomy
Children with Prader-Willi syndrome may receive relief from sleep disorders after undergoing an adenotonsillectomy, suggests a new study from Nationwide Children’s Hospital published in the November print issue of the Archives of Otolaryngology-Head an…
Simple, accurate testing protocol to determine driving fitness in individuals with MS
A simple, accurate testing protocol to determine driving fitness in individuals with multiple sclerosis is the aim of a three-year study at Georgia Health Sciences University.
Researchers discover new cause of hydrocephalus
Researchers at the University of Iowa have discovered a new cause of hydrocephalus, a devastating neurological disorder that affects between one and three of every 1,000 babies born. Working in mice, the researchers identified a cell signaling defect, …
Carl Zeiss Meditec introduces new family of OCT products at 2012 AAO-APAO Joint Meeting
Medical technology manufacturer Carl Zeiss Meditec introduced a new family of OCT products spanning the full spectrum of multi-modality imaging for retinal disease and glaucoma at the 2012 Joint Meeting of the American Academy of Ophthalmology and the …
FDA approves Cook’s Zilver PTX drug-eluting peripheral stent
Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the Unit…
Latest in optometry: headache link debunked; iPads open up new vista
The latest research in optometry finds no link between headaches and refractive errors in children under the age of 18 years – and a clinical purpose for iPads.
Mini-stent shows promising glaucoma control
The implantation of a microstent into the eyes of patients with open-angle glaucoma could remove their need to use eye drops to reduce intraocular pressure, show the 1-year results of a clinical trial.
Hydrus stent may significantly reduce eye pressure in glaucoma patients
A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, according to year-one clinical trial results for the device.
Automated eye tests best for toddlers
Children under the age of 4 years benefit from instrument-based vision screening rather than visual acuity tests since the former is quick, requires minimal cooperation of the child, and is not dependent on their behavioral responses, says a policy sta…
Omeros to present results from first pivotal Phase 3 trial of OMS302 at AAO annual meeting
Omeros Corporation today reported that it will present data from its first pivotal Phase 3 clinical trial evaluating OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will take place from November 10 through November 13 in Chi…
FDA accepts Merck’s suvorexant NDA for standard review
Merck, known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for suvorexant, the company’s investigational insomnia medicine, has been accepted for standard review by the U.S. Food and Drug Administratio…
Corneal limbal stromal cells could lead to new treatments for eye conditions
Eye experts and scientists at the University of Southampton have discovered specific cells in the eye which could lead to a new procedure to treat and cure blinding eye conditions.
Ocular sebaceous carcinoma rare, but often misdiagnosed in UK
Ocular sebaceous carcinoma is rare in the UK, say researchers in the British Journal of Ophthalmology.
One-day seminar to explore ophthalmic innovations
The newest ophthalmic innovations with market potential will be the focus of a one-day seminar in Seattle on May 3, 2013 that will connect scientists, venture capitalists, pharmaceutical representatives and others.
Top-line results from Aerie Pharmaceuticals’ AR-13324 Phase 2a study on glaucoma
Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.
Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension
Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with …
Mass. Eye and Ear opens new outpatient surgical center in Longwood/Mission Hill area of Boston
Massachusetts Eye and Ear, along with the Beal Companies, LLP, today celebrated the grand opening of its new outpatient surgical center at 800 Huntington Avenue in the Longwood/Mission Hill area of Boston. The location will provide access to Mass. Eye …
Gas superior to air tamponade in lower quadrant vitrectomy
Gas and air are suitable tamponading agents for use during vitrectomy for rhegmatogenous retinal detachment, however air tamponade should only be used in cases that are restricted to the superior quadrants, study findings show.
Video-article details new laser-activated bio-adhesive polymer
A new video-article in JoVE, Journal of Visualized Experiments, details the use of a new laser-activated bio-adhesive polymer. The chitosan-based polymer, SurgiLux, was developed by scientists at the University of New South Wales.